Chemotherapy, Immunotherapy, Targeted therapy for gastric cancer, esophageal cancer
This is the third video in our short series on the role of chemotherapy, immunotherapy, and targeted therapy for gastric cancer and esophageal cancer as well as gastro-esophageal junction cancer - adenocarcinoma. This series has been taken by our faculty Dr. Nilesh Lokeshwar who is a senior medical oncologist at Lilavati hospital and research center, Mumbai, Maharashtra, India.
Links to other two videos Chemotherapy in gastric and esophageal cancer - 1 - https://youtu.be/eRKZXflmnnw
Gastric cancer / Stomach cancer - Basics, hereditary predisposition, and molecular classification - https://youtu.be/FE6a3r5vveQ
In the current video, the emphasis is on adjuvant chemotherapy - chemotherapy after surgery. Then he discusses the current evidence on the role of adjuvant therapy and some benchmark trials.
This is followed by a brief discussion on the role of mutation analysis in gastric cancer and targeted therapy as well as immunotherapy. One important point highlighted is the key on when not to give neoadjuvant therapy and that is in MSI-H patients.